PAVmed | 10-Q: FY2025 Q3 Revenue Misses Estimate at USD 5 K

Revenue: As of FY2025 Q3, the actual value is USD 5 K, missing the estimate of USD 12.5 K.

EPS: As of FY2025 Q3, the actual value is USD -0.29.

EBIT: As of FY2025 Q3, the actual value is USD -4.846 M.

Segment Revenue

• Revenue for the three months ended September 30, 2025 was $5, compared to $996 for the same period in 2024. For the nine months ended September 30, 2025, revenue was $19, compared to $2,985 in 2024.

Operational Metrics

• Operating loss for the three months ended September 30, 2025 was -$4,844, compared to -$11,578 for the same period in 2024. For the nine months ended September 30, 2025, operating loss was -$15,003, compared to -$39,300 in 2024.
• Net income (loss) attributable to PAVmed Inc. for the three months ended September 30, 2025 was -$5,383, compared to $64,399 for the same period in 2024. For the nine months ended September 30, 2025, net income was $1,664, compared to $38,360 in 2024.

Cash Flow

• Net cash flows used in operating activities for the nine months ended September 30, 2025 were -$3,655, compared to -$33,648 for the same period in 2024.
• Net cash flows used in investing activities for the nine months ended September 30, 2025 were -$17, compared to -$16,180 for the same period in 2024.
• Net cash flows provided by financing activities for the nine months ended September 30, 2025 were $5,590, compared to $30,954 for the same period in 2024.

Unique Metrics

• Management fee income for the three months ended September 30, 2025 was $3,150, compared to $700 for the same period in 2024. For the nine months ended September 30, 2025, management fee income was $9,450, compared to $700 in 2024.

Future Outlook and Strategy

• Core Business Focus: The company plans to continue supporting the commercial expansion and execution of EsoGuard, focusing on strategic partnerships to expand access to the Veris Cancer Care Platform, and developing an implantable physiological monitor.
• Non-Core Business: The company is exploring external innovations that fulfill project selection criteria without limiting to any target sector, specialty, or condition.
• Priority: Emphasis is placed on strategic partnerships and product development to achieve meaningful inflection points along the path to commercialization.